News
TKPHF
35.00
NaN%
--
Abivax appoints Michael Nesrallah as chief commercial officer
TipRanks · 22h ago
Axsome Inks Agreement To Obtain Exclusive Global Rights To TAK-063 From Takeda
NASDAQ · 1d ago
Axsome Therapeutics enters TAK-063 asset purchase agreement with Takeda
TipRanks · 1d ago
Alumis shares should trade higher on ‘major success’ at AAD, says Ramond James
TipRanks · 3d ago
Kamada: From Buy To Hold After 22.4% Surge (Rating Downgrade)
Seeking Alpha · 3d ago
Alumis price target raised to $55 from $50 at Oppenheimer
TipRanks · 3d ago
Weekly Report: what happened at TKPHF last week (0323-0327)?
Weekly Report · 3d ago
Takeda’s Oral Psoriasis Drug Zasocitinib Shows Strong Phase 3 Results
TipRanks · 3d ago
Takeda's Zasocitinib Shows Rapid, Durable Skin Clearance In Phase 3 Psoriasis Trials
NASDAQ · 4d ago
Takeda announces new data from Phase 3 studies of TAK-279
TipRanks · 4d ago
Takeda Sets June CEO Handover to Julie Kim and Overhauls Board Line-up
TipRanks · 03/26 07:00
Takeda: 'Hold' Despite Performance In 2025-2026
Seeking Alpha · 03/25 21:24
Takeda Unveils Cost-Saving Transformation to Fund Next Wave of Drug Launches
TipRanks · 03/25 08:53
Alkermes price target lowered to $43 from $45 at Piper Sandler
TipRanks · 03/24 10:42
Weekly Report: what happened at TKPHF last week (0316-0320)?
Weekly Report · 03/23 10:04
Weekly Report: what happened at TKPHF last week (0309-0313)?
Weekly Report · 03/16 10:04
Weekly Report: what happened at TKPHF last week (0302-0306)?
Weekly Report · 03/09 10:04
Protagonist Therapeutics price target raised to $100 from $86 at Wedbush
TipRanks · 03/02 13:51
Takeda, Protagonist announce FDA acceptance of rusfertide new drug application
TipRanks · 03/02 10:30
Weekly Report: what happened at TKPHF last week (0223-0227)?
Weekly Report · 03/02 10:04
More
Webull provides a variety of real-time TKPHF stock news. You can receive the latest news about Takeda Pharmaceutical Co Ltd through multiple platforms. This information may help you make smarter investment decisions.
About TKPHF
Takeda Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research, development, manufacturing and global sales of a wide range of pharmaceuticals. Its main business areas are divided into six, including gastroenterology, rare diseases, plasma-derived therapies, oncology (cancer), vaccines, and neuroscience (neuropsychiatric disorders). In research and development, the Company focuses on three priority disease areas, including gastroenterology and inflammatory diseases, neuroscience, and oncology, and also focuses on plasma-derived therapies.